

【Therapeutic category】 429 Other antitumor agents
【Non-proprietary name】 Ixazomib citrate
【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (N/A)	11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Thrombotic microangiopathy</u> <u>Thrombotic microangiopathy including thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome may occur. If anaemia accompanied by schizocytes, thrombocytopenia, renal impairment, etc. are observed, appropriate measures should be taken.</u>

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.